Catalyst Wire Dossier Catalyst Wire Dossier

VAX102 (M2e-flagellin) Universal Influenza Vaccine

M2e-flagellin universal influenza vaccine · VaxInnate Corporation
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VAX102 (M2e-flagellin) Universal Influenza Vaccine, covering 2011-08-22 to 2011-08-22. Get the full timeline:

Most recent: Clinical Trial Update: Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults [Phase 1, Phase 2]

See pricing